Evidence map›Paper›PMID 41881499›Full record

ArticleJournal for immunotherapy of cancer2026

Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production.

Clare E Murray, Carlos O Ontiveros, Jordan Wentworth, Paige Blinkiewicz, Bernice Leung, Haiyan Bai, Nathaniel Spicer, Anja Holtz, Chris Tanner, Akshaya Balasubramanian and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Clare E MurrayGraduate School of Biomedical Sciences, University of Texas Health San Antonio, San Antonio, Texas, USA.
Carlos O OntiverosGraduate School of Biomedical Sciences, University of Texas Health San Antonio, San Antonio, Texas, USA.
Jordan WentworthDartmouth Health, Lebanon, New Hampshire, USA.
Paige BlinkiewiczDepartment of Biochemistry and Cell Biology, Dartmouth College Geisel School of Medicine, Lebanon, New Hampshire, USA.
Bernice LeungDepartment of Microbiology and Immunology, Dartmouth College Geisel School of Medicine, Lebanon, New Hampshire, USA.
Haiyan BaiDartmouth Health, Lebanon, New Hampshire, USA.
Nathaniel SpicerDepartment of Microbiology and Immunology, Dartmouth College Geisel School of Medicine, Lebanon, New Hampshire, USA.
Anja HoltzDepartment of Microbiology and Immunology, Dartmouth College Geisel School of Medicine, Lebanon, New Hampshire, USA.
Chris TannerDepartment of Microbiology and Immunology, Dartmouth College Geisel School of Medicine, Lebanon, New Hampshire, USA.
Akshaya BalasubramanianDepartment of Microbiology and Immunology, Dartmouth College Geisel School of Medicine, Lebanon, New Hampshire, USA.ORCID http://orcid.org/0000-0001-6629-8442
Wenjing LiDepartment of Biochemistry and Structural Biology, University of Texas Health, San Antonio, Texas, USA.
Eloise DrayDepartment of Biochemistry and Structural Biology, University of Texas Health, San Antonio, Texas, USA.
Weixing ZhaoDepartment of Biochemistry and Structural Biology, University of Texas Health, San Antonio, Texas, USA.
Tyler J CurielDartmouth Health, Lebanon, New Hampshire, USA tyler.j.curiel@dartmouth.edu.ORCID http://orcid.org/0000-0001-6962-9411

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
The role of tumor cell-of-origin-specific PDL1 on tumorigenesis and tumor progressionF31CA281345 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Carlos Oscar Ontiveros · 2023 to 2026
$174k
NCI NIH HHS F31 CA281345NCI NIH HHS P30 CA023108
6 · The paper itself

Abstract

backgroundPoly-ADP ribose polymerase inhibitors (PARPi) are well-known to treat tumors that are deficient in homologous recombination (HR) DNA repair. However, PARPi can treat breast cancer gene (BRCA) wild-type tumors, the mechanisms behind which are not fully elucidated. We previously reported that tumor-intrinsic programmed death ligand-1 (PD-L1) signals promote HR, and that genetic tumor PD-L1

methodsWe used control and genetically modified murine and human tumor cell lines to demonstrate signaling outcomes and treatment efficacy of olaparib and telmisartan alone or combined

resultsThe FDA-approved angiotensin II receptor blocker (ARB) antihypertensive telmisartan depleted tumor PD-L1, synergized with PARPi, and augmented PARPi-induced DNA damage. Surprisingly, telmisartan improved PARPi independently of tumor PD-L1, which expands telmisartan applicability to improve PARPi in PD-L1

conclusionsTelmisartan depletes tumor PD-L1 but has significant PD-L1-independent clinical translational potential to improve PARPi in BRCA wild-type (WT) tumors and augment tumor immunogenicity.

Indexed as

Homologous RecombinationInterferon Type IPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsTelmisartanAnimalsCell Line, TumorDrug SynergismFemaleHumansMiceInterferon Type IolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsTelmisartanBreast CancerCombination therapyImmune modulatoryImmunotherapyOvarian Cancer

Identifiers

PMID41881499
PMCPMC13034393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.